A Study to Evaluate the Safety and Efficacy of a Nasal Spray to Treat Seasonal Allergies

Randomized, Double-Blind, Placebo-Controlled Trial of the Safety and Efficacy of MP03-36 in Patients With Seasonal Allergic Rhinitis

The Purpose of this study is to evaluate the safety and efficacy of MP03-36 (0.15% azelastine hydrochloride)at dosages of 2 sprays per nostril once daily and 2 sprays per nostril twice daily in patients with seasonal allergic rhinitis.

Study Overview

• Status: Completed
• Conditions: Seasonal Allergic Rhinitis
• Intervention / Treatment: Drug: azelastine hydrochloride 0.15% Nasal Spray; Drug: azelastine hydrochloride 0.15% and Placebo; Drug: Azelastine 0.1%, Nasal Spray

• Study Type: Interventional
• Enrollment (Actual): 617
• Phase: Phase 3

Contacts and Locations

Study Locations

• United States
  • California
    • Fountain Valley, California, United States, 92708
      • AABI Associates Medical Group
    • Long Beach, California, United States, 90806
      • West Coast Clinical Trials
    • Los Angeles, California, United States, 90025
      • Allergy Research Foundation
    • Mission Viejo, California, United States, 92691
      • Southern California Research
    • Roseville, California, United States, 95678
      • Allergy Medical Group
    • San Diego, California, United States, 92120
      • Allergy Associates Medical Group
    • San Jose, California, United States, 95117
      • Allergy and Asthma Associates of CA
  • Colorado
    • Colorado Springs, Colorado, United States, 80907
      • The William Storms Allergy Clinic
    • Denver, Colorado, United States, 80230
      • Colorado Allergy and Asthma Centers, PC
  • Georgia
    • Savannah, Georgia, United States, 31406
      • Coastal Allergy and Asthma P.C.
  • Kansas
    • Overland Park, Kansas, United States, 66210
      • Kansas City Allergy and Asthma
  • Maryland
    • Wheaton, Maryland, United States, 20902
      • Institute for Asthma and Allergy, P.C.
  • Massachusetts
    • N. Dartmouth, Massachusetts, United States, 02747
      • Northeast Medical Research Associates, Inc.
  • Minnesota
    • Minneapolis, Minnesota, United States, 55402
      • Clinical Research Institute
  • Nebraska
    • Papillion, Nebraska, United States, 68046
      • The Asthma and Allergy Center, PC
  • New Jersey
    • Ocean, New Jersey, United States, 07712
      • Atlantic Allergy, Asthma & Immunology
    • Skillman, New Jersey, United States, 08558
      • Princeton Center for Clinical Research
  • New York
    • Rochester, New York, United States, 14618
      • Allergy and Asthma Institue of Rochester
  • North Carolina
    • Raleigh, North Carolina, United States, 27607
      • North Carolina Clinical Research
  • Ohio
    • Cincinnati, Ohio, United States, 45231
      • Clinical Research Center
  • Oklahoma
    • Edmond, Oklahoma, United States, 73003
      • Oklahoma Institute of Allergy and Asthma
  • Pennsylvania
    • Collegeville, Pennsylvania, United States, 19426
      • Allergy and Asthma Consultants of NJ-PA, P.C
    • Easton, Pennsylvania, United States, 18045
      • Valley Clinical Research Center
    • Pittsburgh, Pennsylvania, United States, 15241
      • Allergy and Clinical Immunology Associates
  • Texas
    • Austin, Texas, United States, 78731
      • Allergy Asthma Associates Research Dept.
    • Dallas, Texas, United States, 75231
      • AARA Research Center
    • Dallas,, Texas, United States, 75234
      • Research Across America
    • New Braunfels, Texas, United States, 78130
      • Central Texas Health Research
    • San Antonio, Texas, United States, 78229
      • Sylvana Research Associates
    • Waco, Texas, United States, 76712
      • Allergy and Asthma Center

Participation Criteria

Eligibility Criteria

• Ages Eligible for Study: 8 years and older (Child, Adult, Older Adult)
• Accepts Healthy Volunteers: No
• Genders Eligible for Study: All

Description

Inclusion Criteria:

• Male and female patients 12 years of age and older
• Provide written informed consent/pediatric assent. If the patient is a minor, a parent or legal guardian must give written informed consent
• Screening Visit: Have a 12-hour reflective total nasal symptoms score ( TNSS) of at least 8 out of a possible 12 and a congestion score of 2 or 3 on Day -7
• Randomization Visit: Have a 12-hour reflective total nasal symptoms score (TNSS) (AM or PM) of at least 8 on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1) during the Lead-in Period. In addition, an AM or PM nasal congestion score of 2 or 3 must have been recorded on 3 separate assessments (one of which was within 2 days of Day 1, and can include the morning of Day 1).
• Must have taken at least 10 doses of study medication during the lead-in period
• Randomization Visit: An instantaneous (TNSS) of ≥ 8 before beginning the onset of action assessment on Day 1
• Willing and able to comply with the study requirements
• At least a 2-year history of seasonal allergic rhinitis (SAR) during the fall pollen allergy season
• The presence of IgE-mediated hypersensitivity to local fall pollen confirmed by a positive response to either skin prick or intradermal testing within the last year. A positive response is defined as a wheal diameter of at least 3 mm larger than the control for the skin prick test or at least 7 mm larger than the control for the intradermal test.
• General good health and free of any disease or concomitant treatment that could interfere with the interpretation of the study results as determined by the investigator or the sponsor's medical officer
• Patients receiving immunotherapy injections (antigen desensitization) must be on a stable maintenance regimen for at least 30 days before the first study visit (adjustments to regimen following a brief period of missed injections does not preclude participation). Patients who are on maintenance doses of sublingual immunotherapy may be considered for the trial on a case-by-case basis after discussion with the sponsor's medical monitor or designee.

Exclusion Criteria:

• The use of any investigational drug within 30 days prior to Day -7. No investigational products are permitted for use during the conduct of this study
• Presence of any hypersensitivity to drugs similar to azelastine and to either sorbitol or sucralose (Splenda® brand sweetener)
• Women who are pregnant or nursing
• Women of childbearing potential who are not abstinent and not practicing a medically acceptable method of contraception
• Respiratory tract infections within two weeks prior to Day -7
• Respiratory Infections requiring oral antibiotic treatment two weeks prior to Day -7
• Other nasal disease(s) likely to affect deposition of intranasal medication, such as sinusitis, rhinitis medicamentosa or clinically significant polyposis or nasal structural abnormalities
• Patients with asthma (with the exception of mild, intermittent asthma)
• Patients with significant pulmonary disease
• Patients with a known history of alcohol or drug abuse
• Existence of any surgical or medical condition, which in the opinion of the investigator or sponsor, might significantly alter the absorption, distribution, metabolism, or excretion of study drug
• Clinically relevant abnormal physical findings within 1 week of randomization which, in the opinion of the investigator, would interfere with the objectives of the study or that may preclude compliance with the study procedures
• Planned travel outside the study area during the study period
• Family members and employees should be excluded
• Patients who received prohibited medications within specified timepoints in the protocol.

Study Plan

How is the study designed?

Design Details

• Primary Purpose: Treatment
• Allocation: Randomized
• Interventional Model: Factorial Assignment
• Masking: Triple

Number of Arms

4

Arms and Interventions

Participant Group / Arm	Intervention / Treatment
Active Comparator: MP03-36 Nasal Spray; azelastine hydrochloride 0.15%	Drug: azelastine hydrochloride 0.15% Nasal Spray; 1644 mcg, 2 sprays per nostril twice daily AM & PM); Other Names: astepro .15%
Active Comparator: MP03-36 and Placebo Nasal Spray; azelastine hydrochloride 0.15% and Placebo	Drug: azelastine hydrochloride 0.15% and Placebo; 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM); Other Names: Astepro.15%
Active Comparator: Azelastine 0.1%, Nasal Spray	Drug: Azelastine 0.1%, Nasal Spray; 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM); Other Names: Astepro
Placebo Comparator: Placebo Nasal Sapray; 0mg, 2 sprays per nostril twice daily AM & PM)	Drug: azelastine hydrochloride 0.15% Nasal Spray; 1644 mcg, 2 sprays per nostril twice daily AM & PM); Other Names: astepro .15%; Drug: azelastine hydrochloride 0.15% and Placebo; 822 mcg azelastine hydrochloride 0.15%, 2 sprays per nostril once daily (AM) and 0mg placebo spray 2 sprays per nostril once daily (PM); Other Names: Astepro.15%; Drug: Azelastine 0.1%, Nasal Spray; 1096 mcg, Azelastine 0.1%,2 sprays per nostril twice daily (AM & PM); Other Names: Astepro

What is the study measuring?

Primary Outcome Measures

Outcome Measure	Time Frame
Change from baseline in 12-hour reflective total nasal symptoms score(TNSS) for the entire 14-day study period compared to placebo	14 Days

Secondary Outcome Measures

Outcome Measure	Time Frame
Change from baseline in instantaneous total nasal symptoms score (TNSS) for the entire 14-day study period compared to placebo	14 Days
Change from baseline to Day 14 in Roland Quality of Life Questionnaire (RQLQ )compared to placebo	14 Days
Change From Baseline on Direct Visual Nasal Exams	14 Days

Collaborators and Investigators

• Sponsor: Meda Pharmaceuticals

Study record dates

Study Major Dates

• Study Start: August 1, 2006
• Primary Completion (Actual): November 1, 2006
• Study Completion (Actual): April 1, 2008

Study Registration Dates

• First Submitted: June 6, 2011
• First Submitted That Met QC Criteria: June 7, 2011
• First Posted (Estimate): June 8, 2011

Study Record Updates

• Last Update Posted (Estimate): October 6, 2011
• Last Update Submitted That Met QC Criteria: October 5, 2011
• Last Verified: October 1, 2011

More Information

Terms related to this study

• Additional Relevant MeSH Terms: Infections; Respiratory Tract Infections; Respiratory Tract Diseases; Immune System Diseases; Hypersensitivity, Immediate; Otorhinolaryngologic Diseases; Respiratory Hypersensitivity; Hypersensitivity; Nose Diseases; Rhinitis; Rhinitis, Allergic; Rhinitis, Allergic, Seasonal; Physiological Effects of Drugs; Neurotransmitter Agents; Molecular Mechanisms of Pharmacological Action; Autonomic Agents; Peripheral Nervous System Agents; Enzyme Inhibitors; Bronchodilator Agents; Anti-Asthmatic Agents; Respiratory System Agents; Anti-Allergic Agents; Histamine H1 Antagonists; Histamine Antagonists; Histamine Agents; Histamine H1 Antagonists, Non-Sedating; Lipoxygenase Inhibitors; Azelastine
• Other Study ID Numbers: MP433